Trial Profile
Phase Ib / II Study of Anlotinib Combined With Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 17 Sep 2018 Planned primary completion date changed from 15 Aug 2021 to 22 Aug 2021.
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.
- 27 Aug 2018 New trial record